Related Experiment Video

Updated: Jul 13, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

[Review of progressive multifocal leukoencephalopathy]

Shuji Kishida1

  • 1Department of Neurology, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|August 19, 2007
PubMed

Insights

Progressive multifocal leukoencephalopathy (PML), a fatal brain disease, is caused by JC virus reactivation in immune-deficient individuals, particularly those with AIDS. Current treatments focus on immune restoration, as specific therapies are lacking and outcomes remain poor.

Area of Science:

  • Neurology
  • Virology
  • Immunology

Context:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, fatal demyelinating disease of the central nervous system.
  • PML is caused by the reactivation of the JC virus (JCV) in immunocompromised individuals.
  • The prevalence of PML has increased significantly, particularly in patients with acquired immunodeficiency syndrome (AIDS).

Purpose:

  • To review the current understanding of PML, its association with AIDS, and epidemiological trends.
  • To highlight the challenges in treating PML and the importance of immune reconstitution.
  • To emphasize the need for improved diagnostic and therapeutic strategies for PML.

Summary:

  • PML is a severe neurological condition resulting from JC virus reactivation, predominantly affecting individuals with compromised cellular immunity, such as those with AIDS.
  • While combined antiretroviral therapy (cART) can improve immune status in AIDS-PML patients, it does not directly treat PML, and deficits are often permanent.
  • The Japanese epidemiological survey indicates a rising incidence of AIDS-associated PML.

Impact:

  • PML poses a significant threat to immunocompromised populations, necessitating urgent development of effective treatments.
  • Early detection through improved diagnostic modalities is crucial for potentially better patient outcomes.
  • Further research into specific anti-JCV therapies and immune-based strategies is essential for combating PML.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Related Concept Videos

Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...